In September 2011, Dong-A Socio Holdings (formerly Dong-A Pharmaceutical) and Japan's Meiji Seika Pharma entered into a comprehensive business partnership covering areas of R&D, production, and marketing to enter the biosimilar business that was seen as a future growth driver in the biopharmaceutical industry. In particular, the key aspect of this partnership was the construction of a globally GMP-compliant bioplant, which marked the beginning of the establishment of STgen Bio.

In coordination with the completion of the plant, the two companies established a joint venture, DM Bio (now, STgen Bio), to collaboratively operate the plant and undertake business operations in the future. Through the establishment of facilities and technologies that can efficiently produce drug substances and drug products for various contract manufacturing, we have been conducting a biopharmaceutical production business that complies with global regulations.

In October 2021, in order to promote swift decision-making and focus on the development and launch of the psoriasis biosimilar (DMB-3115), the company centralized its governance structure under Dong-A Socio Holdings and rebranded as STgen Bio in March 2022. Through the manufacturing and supply of DMB-3115, the joint development project between the two companies, STgen Bio aims to expand its market reach beyond the Japanese market and into the global market such as US and Europe.